Continuous Treatment with Oxalate Changes Renal Physiology and Morphology (DK0750
草酸盐连续治疗改变肾脏生理和形态(DK0750
基本信息
- 批准号:7478048
- 负责人:
- 金额:$ 22.05万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-09-15 至 2009-08-31
- 项目状态:已结题
- 来源:
- 关键词:AdhesionsAdverse effectsAffectApatitesApoptosisAspartate TransaminaseBasement membraneBasic ScienceBilirubinBindingBiological AssayBlood Urea NitrogenBlood VesselsBlood urea nitrogen measurementBone remodelingBowman&aposs spaceBromodeoxyuridineCalcium OxalateCalculiCardiomyopathiesCause of DeathChemicalsChemistryChromatographyChronicClassificationClinicalClinical MarkersConditionConfocal MicroscopyContralateralCreatinineCrystal FormationDNA NucleotidylexotransferaseDNTT geneDataDepositionDevelopmentDiseaseDissociationDistressDoseElectrolytesElectron MicroscopyEndocrineEndocytosisEnsureEnteralEpithelialEpitheliumEvaluationEventExcretory functionExperimental Water DeprivationExposure toFosteringFrozen SectionsFutureGoalsHealthHeartHepaticHyperoxaluriaImmunofluorescence ImmunologicImmunofluorescence MicroscopyIn VitroIncidenceIndividualInflammatory Bowel DiseasesInjuryIonsJejunoileal BypassKidneyKidney FailureKidney PapillaKidney TransplantationLabelLifeLightLiverMediatingMessenger RNAMicroscopyModelingMorphologyMyocardialNephrocalcinosisNephrolithiasisNephronsOperative Surgical ProceduresOpticsOsteocalcinOxalatesParaffin EmbeddingPathologyPatientsPenetrationPerformancePerfusionPhasePhosphotransferasesPhysiologicalPhysiologyPlantsPlasmaPlasticsPlayPotassium OxalatePredispositionPreventionPrimary HyperoxaluriaPrincipal InvestigatorProcessProtocols documentationPublic HealthQuality of lifeRattusReaction TimeRegulatory PathwayRenal functionRenal pelvisRenal tubule structureReportingResearch PersonnelReverse Transcriptase Polymerase Chain ReactionRisk FactorsRoleSamplingSerumStaining methodStainsStandards of Weights and MeasuresSymptomsTechnical ExpertiseTimeTissue HarvestingTissuesTransmission Electron MicroscopyTreatment ProtocolsUreterUrineValidationWestern BlottingWorkbonebone turnovercalcium phosphateclinically relevantcysteine rich proteindaydosagein vivoin vivo Modelliver functionliver transplantationmonolayernovelparacrinepreventprogramsrenal epitheliumresearch studyresponsesizesuccesstongue papillaurinary
项目摘要
DESCRIPTION (provided by applicant): The role that oxalate plays in calcium oxalate (CaOx) nephrocalcinosis and oxalate driven nephrolithiasis is not well understood. There is accruing evidence that in addition to crystal formation, oxalate promotes these conditions through its interactions with the renal epithelium, interstitium and vasculature. Differing susceptibilities to these effects may partially explain why individuals with similar risk factors have do not have similar clinical symptoms. This proposal will utilize two versions of the minipump model to study these interactions. The standard 14D protocol models moderate-to-severe hyperoxaluria in that it induces a greater than or equal to 3x increase in oxalate excretion and intratubular CaOx-nephrocalcinosis. The LongDose protocol will model the more common mild-to-moderate hyperoxaluria by inducing less than or equal to 1.5-2x increase in oxalate excretion over a 4wk period and the induction of mixed CaOx-/CaP- nephrocalcinosis. A novel aspect of this proposal is that ion chromatography and polarizing microscopy/ Yasue staining + morphometric analysis will be used to correlate oxalate's effects on specific segments of the nephron, interstitium or vasculature with intrarenal oxalate concentrations and crystal deposition. Dose response and time course studies will identify those changes which occur prior to crystal deposition and thus could be fostering nephrocalcinosis. In Specific Aim 1, the effects of 360 muM KOx/24hr for 14D on liver function, cardiomyopathy, and bone remodiling will be determined and the LongDose protocol will be developed. Specific Aim 2 will utilize RT-PCR, Northern & Western blotting and immunofluorescence to identify changes in the expression of segment specific, general distress, vasculature distress and stone disease makers during continuous, steady exposure to oxalate. Specific Aim 3 will utilize transmission electron microscopy and immunofluorescence to identify segments of the nephron and regions of the interstitium and vasculature that show morphological damage, apoptosis or proliferation during continuous, steady exposure to oxalate. Relevance to Public Health: This proposal investigates oxalate's effects on specific regions of the kidney during the early phases of CaOx- nephrocalcinosis and oxalate driven stone disease using the rat minipump model. The objective is to identify those effects which promote these conditions. Future work will determine the mechanism of these effects with the goal of developing an effective preventative therapy.
描述(由申请人提供):草酸盐在草酸钙(CaOx)肾钙化症和草酸盐驱动的肾结石中的作用尚不清楚。越来越多的证据表明,除了晶体形成外,草酸盐还通过与肾上皮、间质和脉管系统的相互作用促进这些疾病的发生。对这些影响的不同易感性可能部分解释了为什么具有相似风险因素的个体没有相似的临床症状。本提案将利用两个版本的迷你泵模型来研究这些相互作用。标准14D方案模型为中度至重度高草酸血症,因为它诱导草酸盐排泄增加大于或等于3倍,以及小管内caox肾钙化症。长剂量方案将模拟更常见的轻度至中度高草酸尿,在4周内诱导草酸排泄量增加小于或等于1.5-2倍,并诱导混合CaOx-/CaP-肾钙化症。该建议的一个新颖方面是,将使用离子色谱和偏光显微镜/安素染色+形态计量学分析来将草酸盐对肾单位、间质或脉管系统的特定部分的影响与肾内草酸盐浓度和晶体沉积联系起来。剂量反应和时间过程研究将确定在晶体沉积之前发生的变化,从而可能促进肾钙化症。在Specific Aim 1中,将确定360mmkox /24hr对14D的肝功能、心肌病和骨重塑的影响,并制定长剂量方案。Specific Aim 2将利用RT-PCR、Northern & Western blotting和免疫荧光来识别连续、稳定暴露于草酸盐期间,特定节段、一般窘迫、血管窘迫和结石疾病的表达变化。特异性目的3将利用透射电子显微镜和免疫荧光来识别在连续、稳定暴露于草酸盐中表现出形态学损伤、细胞凋亡或增殖的肾元片段和间质和血管区域。与公共卫生的相关性:本建议使用大鼠迷你泵模型研究草酸盐在CaOx-肾钙化症和草酸盐驱动的结石疾病早期阶段对肾脏特定区域的影响。我们的目标是找出导致这些情况的因素。未来的工作将确定这些影响的机制,目标是开发有效的预防治疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SUSAN RUTH MARENGO其他文献
SUSAN RUTH MARENGO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SUSAN RUTH MARENGO', 18)}}的其他基金
Continuous Treatment with Oxalate Changes Renal Physiology and Morphology (DK0750
草酸盐连续治疗改变肾脏生理学和形态学 (DK0750
- 批准号:
7147259 - 财政年份:2006
- 资助金额:
$ 22.05万 - 项目类别:
Continuous Treatment with Oxalate Changes Renal Physiology and Morphology (DK0750
草酸盐连续治疗改变肾脏生理学和形态学 (DK0750
- 批准号:
7284407 - 财政年份:2006
- 资助金额:
$ 22.05万 - 项目类别:
INTER ALPHA TRYPSIN INHIBITOR IN CAOX UROLITHIASIS
间α胰蛋白酶抑制剂治疗 CAOX 尿石症
- 批准号:
6517576 - 财政年份:1998
- 资助金额:
$ 22.05万 - 项目类别:
INTER ALPHA TRYPSIN INHIBITOR IN CAOX UROLITHIASIS
间α胰蛋白酶抑制剂治疗 CAOX 尿石症
- 批准号:
2822706 - 财政年份:1998
- 资助金额:
$ 22.05万 - 项目类别:
INTER ALPHA TRYPSIN INHIBITOR IN CAOX UROLITHIASIS
间α胰蛋白酶抑制剂治疗 CAOX 尿石症
- 批准号:
2906404 - 财政年份:1998
- 资助金额:
$ 22.05万 - 项目类别:
INTER ALPHA TRYPSIN INHIBITOR IN CAOX UROLITHIASIS
间α胰蛋白酶抑制剂治疗 CAOX 尿石症
- 批准号:
6381496 - 财政年份:1998
- 资助金额:
$ 22.05万 - 项目类别:
INTER ALPHA TRYPSIN INHIBITOR IN CAOX UROLITHIASIS
间α胰蛋白酶抑制剂治疗 CAOX 尿石症
- 批准号:
6177433 - 财政年份:1998
- 资助金额:
$ 22.05万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 22.05万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 22.05万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 22.05万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 22.05万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 22.05万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 22.05万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 22.05万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 22.05万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 22.05万 - 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
- 批准号:
RGPIN-2018-04753 - 财政年份:2022
- 资助金额:
$ 22.05万 - 项目类别:
Discovery Grants Program - Individual